Onesource Specialty Pharma Limited announced a leadership reshuffle in its senior management, effective July 24, 2026, with Preeti Kalra designated as a Senior Management Personnel (SMP). At the same time, Ravi Kumar, who held the roles of Global Head – Injectables and Head of Corporate Strategy, Portfolio & SPO, has resigned from his SMP position. The company emphasized that the changes are being made within its ongoing efforts to strengthen its management bandwidth as it scales its operations.
Preeti Kalra arrives as an experienced HR leader with over 25 years in biopharma, global development, public service and IT, including leadership roles at Stelis Biopharma, Biocon Biologics, the Bill & Melinda Gates Foundation, Serco and Ernst & Young. Her depth in talent management, leadership development, organizational transformation and culture aligns with Onesource’s priorities as it pursues growth across regions and functions. Her elevation signals a continued emphasis on building leadership capability and organizational effectiveness to support the company’s strategic initiatives.
Ravi Kumar’s departure marks the end of a multi-faceted tenure that encompassed both the injectables portfolio leadership and strategic oversight. The company did not detail any replacement at this time, but the move will likely prompt internal reviews of strategic priorities and portfolio management as Onesource advances its development and manufacturing agenda. With both changes, Onesource continues to refine its senior-management roster to align leadership capacity with its next phase of growth.
The leadership changes come as the Bengaluru-based company, formerly Stelis Biopharma, charts its path forward in a competitive biopharma CDMO landscape, underscoring a focus on strengthening core functions while pursuing ambitious development and manufacturing goals.